GB SCIENCES INC - GBLX STOCK NEWS

Gb Sciences has announced promising results for its cannabinoid-containing therapy aimed at treating cytokine release syndrome (CRS), a severe complication of COVID-19. The research, conducted by Michigan State University, indicated that complex mixtures of synthetic cannabinoids effectively reduced biomarkers associated with CRS and showed potential for use in related conditions. As the Omicron variant emerges, Gb Sciences aims to accelerate development of this therapy, which targets the immune response rather than the virus itself. The company holds several patents and is developing multiple drug candidates.

Gb Sciences has introduced its AI-enabled drug discovery platform, PhAROS™, aimed at accelerating the development of plant-inspired therapies.

By streamlining the drug development pipeline, the company dramatically reduces the time from ideation to candidate selection from seven years to 1.5 years.

Gb Sciences has also secured three U.S. patents for therapies targeting Parkinson's disease, with five preclinical candidates in development. Collaborative partnerships with seven universities and Purisys, Inc. enhance its resource efficiency and supply chain reliability.

Gb Sciences (OTCQB:GBLX) has launched new preclinical studies at the National Research Council of Canada, utilizing its AI-driven PhAROS™ platform to identify novel, plant-inspired formulations aimed at treating depression and anxiety. This marks the company's first non-cannabis formulations in preclinical testing. The formulations are based on a new combination of plant compounds, replacing potentially liver-toxic ingredients from the kava plant with safer alternatives from the Piper plant family. The studies may lead to innovative treatments for mental health disorders.

Gb Sciences (OTCQB: GBLX) has reported promising results from a preclinical study at Michigan State University, indicating the potential of its cannabinoid-containing complex mixtures for treating hyperinflammatory conditions like Cytokine Release Syndrome associated with COVID-19. The company upgraded its provisional patent application to a nonprovisional one on August 18, 2021. The study showcased the mixtures' ability to modulate pro-inflammatory cytokines while maintaining anti-viral immune responses. Gb Sciences aims to advance these findings into clinical trials to address critical health challenges.

Gb Sciences (OTCQB: GBLX) announced that Dr. Andrea Small-Howard, President and Chief Science Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, 2021. The presentation will focus on the company's plant-inspired therapies targeting COVID-related cytokine release syndrome, chronic pain, and Parkinson's disease, along with the proprietary AI-enabled drug discovery platform, PhAROS. Dr. Small-Howard will also share results from a recent proof-of-concept study regarding therapies for hyperinflammation due to COVID-19.

Gb Sciences (OTCQB:GBLX) will present at the SNN Network Summer Virtual Event 2021 on August 18 at 3 PM EST. Dr. Andrea Small-Howard, President and Chief Science Officer, will lead the session, discussing the company's recent shift from cannabis to biotech, emphasizing FDA-regulated pathways for cannabis-based products. Interested investors can attend live via webcast or schedule 1-on-1 meetings through the event platform. Past presentations are accessible later on the conference platform.

GB Sciences has completed a data science study utilizing its PhAROS™ AI-accelerated drug discovery platform, identifying therapeutic mixtures from the Piper plant family for treating anxiety, depression, and pain. The company plans to initiate animal testing for these mixtures next quarter. They have filed additional US patent applications for the identified therapeutic mixtures, which aim to provide effective alternatives to traditional therapies like Kava. GB Sciences is also preparing for a First-in-Man clinical trial for its lead Parkinson's disease program.

GB Sciences has launched an AI-driven drug discovery platform named PhAROS, aimed at revolutionizing the identification of effective plant-based therapeutics. This technology reduces the time and investment needed to develop novel formulations by facilitating early exploration and validation of combinations of active ingredients derived from plants. Initially focused on cannabis, the platform now encompasses diverse natural products. The company has a robust pipeline with multiple preclinical programs targeting complex diseases like Parkinson's, aiming for patient-ready formulations while minimizing side effects.

GB Sciences has announced the promotion of Dr. Andrea Small-Howard to President, retaining her roles as Chief Science Officer and board member. Dr. Small-Howard, a founding member of the company, has significantly contributed to its strategic direction and innovative programs, including a novel AI-enabled drug discovery platform and over 50 patent applications. The company aims to advance its drug pipeline targeting conditions like Parkinson's disease and chronic pain. CEO John Poss emphasizes her importance for the company's future success, focusing on growth in evidence-based medicine.